JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy-Reference-Cited by-同舟云学术

JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy

Published:2020-12-27 Issue:1 Volume:22 Page:66-78
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Babu Govind¹,Chaudhuri Padmaparna²,Rajappa Manoj²,Biswas Manjusha³,Sansar Bipinesh¹,Rajegowda Chethan¹,Radhakrishnan Aneesha²,Advani Jayshree⁴,Tewary Biplab²,Radhakrishnan Padhma²,Thiyagarajan Saravanan²,Chatterjee Aditi²^ORCID,Upadhayaya Ram Shankar⁵,Majumder Pradip K²⁵

Affiliation:

1. Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India

2. Departments of Cancer Biology, Mitra Biotech, Woburn, Massachusetts, USA

3. Molecular Pathology, Mitra Biotech, Woburn, Massachusetts, USA

4. Institute of Bioinformatics, International Technology Park, Bangalore, India

5. Ohm Oncology, Austin, TX, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2020.1831371